STOCK TITAN

Maravai LifeSciences Holdings, Inc. - MRVI STOCK NEWS

Welcome to our dedicated page for Maravai LifeSciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai LifeSciences Holdings stock.

Maravai LifeSciences Holdings, Inc. (symbol: MRVI) is a leading life sciences company dedicated to advancing human health by providing specialized products and services to support the development of drug therapies, diagnostics, and novel vaccines. Formed in March 2014 through a partnership with GTCR, a private equity firm, Maravai LifeSciences has built a portfolio of successful, entrepreneurial life science companies.

Maravai’s portfolio companies are spearheading innovations in life sciences research and bioproduction, offering enabling tools and services that facilitate breakthroughs in genomics, proteomics, and biotherapeutic development. The company’s core business includes two primary segments: Nucleic Acid Production and Biologics Safety Testing. A significant portion of Maravai's revenue is generated from Nucleic Acid Production, which involves the manufacturing and sale of nucleic acid products essential for research and the development of vaccines and therapies.

Maravai LifeSciences has acquired four market-leading companies to date, enhancing its portfolio of products and services. Notably, Vector Laboratories is recognized for its labeling and detection products used in immunohistochemistry and immunofluorescence. Another key entity, TriLink BioTechnologies, continues to advance the field with its innovative solutions.

Recent achievements and ongoing projects underscore Maravai’s commitment to growth and innovation. The company remains focused on expanding its product portfolio, maintaining market leadership, and driving scientific advancements. The latest financial results highlight Maravai's robust performance, with continued revenue growth and strategic investments in new areas of research and development.

Maravai LifeSciences is actively engaged in discussions and presentations at prominent investor forums, such as the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum and the RBC Healthcare Conference, showcasing its leadership and strategic direction. These events provide valuable insights into Maravai’s ongoing initiatives and future outlook.

For more detailed information about Maravai LifeSciences, including recent news and updates, visit the Maravai LifeSciences website.

Rhea-AI Summary

Maravai LifeSciences Holdings (NASDAQ: MRVI) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This key index tracks the performance of biotechnology and pharmaceutical companies listed on Nasdaq, reflecting their market activity. To qualify, companies must meet specific criteria such as market capitalization and trading volume. Maravai, a provider of life science reagents and services supporting drug development and diagnostics, demonstrates its growth potential through this milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.59%
Tags
none
-
Rhea-AI Summary

Maravai LifeSciences (NASDAQ: MRVI) reported a significant 133% revenue increase, reaching $204.8 million for Q3 2021, compared to $87.9 million in Q3 2020. Net income surged 240% to $132.8 million. The company raised its 2021 revenue guidance to $770-$780 million and introduced preliminary 2022 guidance of $840-$880 million. Key growth was driven by Nucleic Acid Production, up 170% year-over-year. Maravai also closed the sale of its Protein Detection segment and published its inaugural Environmental, Social and Governance Report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
Rhea-AI Summary

On November 8, 2021, New England Biolabs (NEB) announced the release of the HiScribe T7 mRNA Kit featuring TriLink's CleanCap Reagent AG. This new kit simplifies mRNA synthesis, offering high yields with a Cap 1 structure, enhancing biological activity while reducing immunogenicity. NEB's kits are scalable for therapeutic mRNA manufacturing, including vaccine production. The collaboration aims to accelerate research and development in mRNA technology. NEB continues to expand its offerings in molecular biology, supporting global vaccine programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
-
Rhea-AI Summary

Maravai LifeSciences (NASDAQ: MRVI) has announced its participation in two upcoming virtual investor conferences in November 2021. CFO Kevin Herde will engage in a fireside chat at the Stifel Healthcare Conference on November 17 at 10:20 a.m. PT and present at the Nasdaq Investor Conference on November 30 at 7:00 a.m. PT. Live webcasts will be available on the company's investor relations website, with archived versions posted shortly after each event. Maravai specializes in life science reagents and services, supporting drug therapy and diagnostics development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
none
-
Rhea-AI Summary

Maravai LifeSciences (NASDAQ: MRVI) will announce its third quarter 2021 financial results after market close on November 10, 2021. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET the same day, which can be accessed by dialing (833) 693-0536 or (661) 407-1576 with conference ID 9136747. Participants can also listen via live or archived webcast on the company's Investors website. Maravai provides essential products for drug therapy, diagnostics, and vaccine development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences earnings
Rhea-AI Summary

Maravai LifeSciences (NASDAQ: MRVI) has announced that its subsidiary, TriLink BioTechnologies, received a new European patent (No. 3352584) for its CleanCap technology, which enhances the production of synthetic mRNA. This patent is crucial for developing mRNA vaccines and therapeutics, facilitating a streamlined manufacturing process that reduces time and costs. Mike Houston, Chief Scientific Officer, highlighted the advantages of CleanCap in improving the efficiency and viability of mRNA constructs, particularly in rapid vaccine responses and personalized cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
Rhea-AI Summary

TriLink BioTechnologies announced its collaboration with EyeGene to supply its proprietary CleanCap® technology and modified uridine triphosphate for the production of EyeGene’s EG-COVID mRNA vaccine, which has received approval for clinical trials from South Korea's MFDS. This partnership marks a significant advancement in mRNA vaccine development, aiming to enhance safety and effectiveness. The vaccine will undergo Phase 1/2a trials, utilizing a cationic liposome delivery system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
partnership covid-19
-
Rhea-AI Summary

Maravai LifeSciences Holdings (NASDAQ: MRVI) announced a public offering of 20 million shares at $50.00 each, set to close on September 14, 2021. The shares are being sold by certain stockholders, with a 30-day option for underwriters to purchase an additional 3 million shares. Maravai will not receive any proceeds from this sale. Key financial institutions such as Morgan Stanley, Jefferies, and Goldman Sachs are managing the offering. The registration statement was declared effective on September 9, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags
none
Rhea-AI Summary

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) announced a public offering of 20 million Class A shares by selling stockholders, with an option for underwriters to purchase an additional 3 million shares. The company will not receive proceeds from this offering, which is under a registration statement filed with the SEC. Morgan Stanley, Jefferies, and Goldman Sachs are managing the offering. The registration statement is pending effectiveness, and no sales can occur until it is active.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
none

FAQ

What is the current stock price of Maravai LifeSciences Holdings (MRVI)?

The current stock price of Maravai LifeSciences Holdings (MRVI) is $5.37 as of December 20, 2024.

What is the market cap of Maravai LifeSciences Holdings (MRVI)?

The market cap of Maravai LifeSciences Holdings (MRVI) is approximately 776.6M.

What does Maravai LifeSciences Holdings, Inc. specialize in?

Maravai LifeSciences specializes in providing products and services that support the development of drug therapies, diagnostics, and novel vaccines, as well as research in genomics, proteomics, and biotherapeutic development.

When was Maravai LifeSciences formed?

Maravai LifeSciences was formed in March 2014 through a partnership with GTCR, a leading private equity firm.

What are the main business segments of Maravai LifeSciences?

The main business segments of Maravai LifeSciences are Nucleic Acid Production and Biologics Safety Testing.

Which companies are part of Maravai LifeSciences' portfolio?

Maravai LifeSciences' portfolio includes Vector Laboratories and TriLink BioTechnologies, among others.

Where can I find the latest financial results of Maravai LifeSciences?

The latest financial results of Maravai LifeSciences can be found on their investor relations website, under News & Events.

How does Maravai LifeSciences support scientific research?

Maravai LifeSciences supports scientific research by providing essential tools and services for genomics, proteomics, and biotherapeutic development.

What recent events has Maravai LifeSciences participated in?

Maravai LifeSciences has participated in events such as the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum and the RBC Healthcare Conference.

How can I access Maravai LifeSciences' presentations at investor forums?

Presentations from investor forums can be accessed via live webcasts on the Maravai LifeSciences Investor Relations website, with archived versions available post-event.

What is the mission of Maravai LifeSciences?

The mission of Maravai LifeSciences is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth.

Where can I find more information about Maravai LifeSciences?

More information about Maravai LifeSciences can be found on their official website at www.maravai.com.

Maravai LifeSciences Holdings, Inc.

Nasdaq:MRVI

MRVI Rankings

MRVI Stock Data

776.59M
119.61M
1.37%
102.83%
4.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO